Intracellular Localization of GGA Accessory Protein P56 in Cell Lines and Cen- Tral Nervous System Neurons
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Autism Multiplex Family with 16P11.2P12.2 Microduplication Syndrome in Monozygotic Twins and Distal 16P11.2 Deletion in Their Brother
European Journal of Human Genetics (2012) 20, 540–546 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Autism multiplex family with 16p11.2p12.2 microduplication syndrome in monozygotic twins and distal 16p11.2 deletion in their brother Anne-Claude Tabet1,2,3,4, Marion Pilorge2,3,4, Richard Delorme5,6,Fre´de´rique Amsellem5,6, Jean-Marc Pinard7, Marion Leboyer6,8,9, Alain Verloes10, Brigitte Benzacken1,11,12 and Catalina Betancur*,2,3,4 The pericentromeric region of chromosome 16p is rich in segmental duplications that predispose to rearrangements through non-allelic homologous recombination. Several recurrent copy number variations have been described recently in chromosome 16p. 16p11.2 rearrangements (29.5–30.1 Mb) are associated with autism, intellectual disability (ID) and other neurodevelopmental disorders. Another recognizable but less common microdeletion syndrome in 16p11.2p12.2 (21.4 to 28.5–30.1 Mb) has been described in six individuals with ID, whereas apparently reciprocal duplications, studied by standard cytogenetic and fluorescence in situ hybridization techniques, have been reported in three patients with autism spectrum disorders. Here, we report a multiplex family with three boys affected with autism, including two monozygotic twins carrying a de novo 16p11.2p12.2 duplication of 8.95 Mb (21.28–30.23 Mb) characterized by single-nucleotide polymorphism array, encompassing both the 16p11.2 and 16p11.2p12.2 regions. The twins exhibited autism, severe ID, and dysmorphic features, including a triangular face, deep-set eyes, large and prominent nasal bridge, and tall, slender build. The eldest brother presented with autism, mild ID, early-onset obesity and normal craniofacial features, and carried a smaller, overlapping 16p11.2 microdeletion of 847 kb (28.40–29.25 Mb), inherited from his apparently healthy father. -
The Cellular Nucleic Acid Binding Protein Regulates the Alzheimer’S Disease Β-Secretase Protein Bace1
University of Kentucky UKnowledge Theses and Dissertations--Molecular and Cellular Biochemistry Molecular and Cellular Biochemistry 2012 THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1 Christopher J. Holler University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Holler, Christopher J., "THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1" (2012). Theses and Dissertations--Molecular and Cellular Biochemistry. 12. https://uknowledge.uky.edu/biochem_etds/12 This Doctoral Dissertation is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Molecular and Cellular Biochemistry by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies. -
BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’S Disease Pathology
Review BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology Gerald Koelsch CoMentis, Inc., South San Francisco, CA 94080, USA; [email protected] Received: 15 September 2017; Accepted: 10 October 2017; Published: 13 October 2017 Abstract: Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disorder characterized by increasing loss in memory, cognition, and function of daily living. Among the many pathologic events observed in the progression of AD, changes in amyloid β peptide (Aβ) metabolism proceed fastest, and precede clinical symptoms. BACE1 (β-secretase 1) catalyzes the initial cleavage of the amyloid precursor protein to generate Aβ. Therefore inhibition of BACE1 activity could block one of the earliest pathologic events in AD. However, therapeutic BACE1 inhibition to block Aβ production may need to be balanced with possible effects that might result from diminished physiologic functions BACE1, in particular processing of substrates involved in neuronal function of the brain and periphery. Potentials for beneficial or consequential effects resulting from pharmacologic inhibition of BACE1 are reviewed in context of ongoing clinical trials testing the effect of BACE1 candidate inhibitor drugs in AD populations. Keywords: Alzheimer’s disease; amyloid hypothesis; BACE1; beta secretase; pharmacology 1. Introduction Alzheimer’s disease (AD) is a fatal progressive neurodegenerative disorder, slowly eroding memory, cognition, and functions of daily living, inevitably culminating in death from pneumonia and infectious diseases resulting from failure to thrive, loss of fine motor skills, and incapacitation. Treatment is limited to therapeutics that alleviate symptoms of memory loss, but are effective for a relatively short duration during and after which disease progression continues. -
Rabbit Anti-RABEP1 Antibody-SL19721R
SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-RABEP1 antibody SL19721R Product Name: RABEP1 Chinese Name: RABEP1蛋白抗体 Neurocrescin; Rab GTPase binding effector protein 1; RAB5EP; Rabaptin 4; Rabaptin Alias: 5; Rabaptin 5alpha; RABPT5; RABPT5A; Renal carcinoma antigen NY REN 17; Renal carcinoma antigen NYREN17. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat, ELISA=1:500-1000IHC-P=1:400-800IHC-F=1:400-800ICC=1:100-500IF=1:100- 500(Paraffin sections need antigen repair) Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 99kDa Cellular localization: The cell membrane Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human RABEP1:501-600/862 Lsotype: IgGwww.sunlongbiotech.com Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. PubMed: PubMed RABEP1 is a Rab effector protein acting as linker between gamma-adaptin, RAB4A and RAB5A. It is involved in endocytic membrane fusion and membrane trafficking of Product Detail: recycling endosomes. Stimulates RABGEF1 mediated nucleotide exchange on RAB5A. -
Sequence and Comparative Analysis of the Chicken Genome Provide Unique Perspectives on Vertebrate Evolution
articles Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution International Chicken Genome Sequencing Consortium* *Lists of participants and affiliations appear at the end of the paper ........................................................................................................................................................................................................................... We present here a draft genome sequence of the red jungle fowl, Gallus gallus. Because the chicken is a modern descendant of the dinosaurs and the first non-mammalian amniote to have its genome sequenced, the draft sequence of its genome—composed of approximately one billion base pairs of sequence and an estimated 20,000–23,000 genes—provides a new perspective on vertebrate genome evolution, while also improving the annotation of mammalian genomes. For example, the evolutionary distance between chicken and human provides high specificity in detecting functional elements, both non-coding and coding. Notably, many conserved non-coding sequences are far from genes and cannot be assigned to defined functional classes. In coding regions the evolutionary dynamics of protein domains and orthologous groups illustrate processes that distinguish the lineages leading to birds and mammals. The distinctive properties of avian microchromosomes, together with the inferred patterns of conserved synteny, provide additional insights into vertebrate chromosome architecture. Genome sequence comparison is a modern extension of the long- standing use of other species as models to illuminate aspects of human biology and medicine. Large-scale genome analyses also highlight the evolutionary dynamics of selective and mutational processes at different chronological scales1–4. We present here results obtained from an extensive analysis of a draft sequence of the chicken genome, which has evolved separately from mammalian genomes for ,310 million years (Myr)4,5 (Fig. -
Analysis of Gga Null Mice Demonstrates a Non- Redundant Role for Mammalian GGA2 During Development
Analysis of Gga Null Mice Demonstrates a Non- Redundant Role for Mammalian GGA2 during Development Jennifer Govero., Balraj Doray., Hongdong Bai¤, Stuart Kornfeld* Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America Abstract Numerous studies using cultured mammalian cells have shown that the three GGAs (Golgi-localized, gamma-ear containing, ADP-ribosylation factor- binding proteins) function in the transport of cargo proteins between the trans- Golgi network and endosomes. However, the in vivo role(s) of these adaptor proteins and their possible functional redundancy has not been analyzed. In this study, the genes encoding GGAs1-3 were disrupted in mice by insertional mutagenesis. Loss of GGA1 or GGA3 alone was well tolerated whereas the absence of GGA2 resulted in embryonic or neonatal lethality, depending on the genetic background of the mice. Thus, GGA2 mediates a vital function that cannot be compensated for by GGA1and/or GGA3. The combined loss of GGA1 and GGA3 also resulted in a high incidence of neonatal mortality but in this case the expression level of GGA2 may be inadequate to compensate for the loss of the other two GGAs. We conclude that the three mammalian GGAs are essential proteins that are not fully redundant. Citation: Govero J, Doray B, Bai H, Kornfeld S (2012) Analysis of Gga Null Mice Demonstrates a Non-Redundant Role for Mammalian GGA2 during Development. PLoS ONE 7(1): e30184. doi:10.1371/journal.pone.0030184 Editor: Ludger Johannes, Institut Curie, France Received October 27, 2011; Accepted December 15, 2011; Published January 26, 2012 Copyright: ß 2012 Govero et al. -
Identification of Key Genes and Pathways for Alzheimer's Disease
Biophys Rep 2019, 5(2):98–109 https://doi.org/10.1007/s41048-019-0086-2 Biophysics Reports RESEARCH ARTICLE Identification of key genes and pathways for Alzheimer’s disease via combined analysis of genome-wide expression profiling in the hippocampus Mengsi Wu1,2, Kechi Fang1, Weixiao Wang1,2, Wei Lin1,2, Liyuan Guo1,2&, Jing Wang1,2& 1 CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing 100101, China 2 Department of Psychology, University of Chinese Academy of Sciences, Beijing 10049, China Received: 8 August 2018 / Accepted: 17 January 2019 / Published online: 20 April 2019 Abstract In this study, combined analysis of expression profiling in the hippocampus of 76 patients with Alz- heimer’s disease (AD) and 40 healthy controls was performed. The effects of covariates (including age, gender, postmortem interval, and batch effect) were controlled, and differentially expressed genes (DEGs) were identified using a linear mixed-effects model. To explore the biological processes, func- tional pathway enrichment and protein–protein interaction (PPI) network analyses were performed on the DEGs. The extended genes with PPI to the DEGs were obtained. Finally, the DEGs and the extended genes were ranked using the convergent functional genomics method. Eighty DEGs with q \ 0.1, including 67 downregulated and 13 upregulated genes, were identified. In the pathway enrichment analysis, the 80 DEGs were significantly enriched in one Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, GABAergic synapses, and 22 Gene Ontology terms. These genes were mainly involved in neuron, synaptic signaling and transmission, and vesicle metabolism. These processes are all linked to the pathological features of AD, demonstrating that the GABAergic system, neurons, and synaptic function might be affected in AD. -
Mouse Gga1 Conditional Knockout Project (CRISPR/Cas9)
https://www.alphaknockout.com Mouse Gga1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Gga1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Gga1 gene (NCBI Reference Sequence: NM_145929 ; Ensembl: ENSMUSG00000033128 ) is located on Mouse chromosome 15. 17 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 17 (Transcript: ENSMUST00000041587). Exon 2~3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Gga1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-83M14 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a gene-trapped allele display decreased birth weight, slow postnatal weight gain, hypoglycemia, increased plasma levels of acid hydrolases, and partial neonatal lethality. Exon 2 starts from about 2.31% of the coding region. The knockout of Exon 2~3 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 3420 bp, and the size of intron 3 for 3'-loxP site insertion: 1064 bp. The size of effective cKO region: ~1666 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 5 17 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Gga1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. -
Entrez ID 1 Symbol 1 Entrez ID 2 Symbol 2 Data Source (R
Supporting Information Table 4. List of human protein-protein interactons. Entrez ID 1 Symbol 1 Entrez ID 2 Symbol 2 Data Source (R: Rual et al; S: Stelzl et al; L: Literature curation) 1 A1BG 10321 CRISP3 L 2 A2M 259 AMBP L 2 A2M 348 APOE L 2 A2M 351 APP L 2 A2M 354 KLK3 L 2 A2M 567 B2M L 2 A2M 1508 CTSB L 2 A2M 1990 ELA1 L 2 A2M 3309 HSPA5 L 2 A2M 3553 IL1B L 2 A2M 3586 IL10 L 2 A2M 3931 LCAT L 2 A2M 3952 LEP L 2 A2M 4035 LRP1 L 2 A2M 4803 NGFB L 2 A2M 5047 PAEP L 2 A2M 7045 TGFBI L 2 A2M 8728 ADAM19 L 2 A2M 9510 ADAMTS1 L 2 A2M 10944 SMAP S 2 A2M 55729 ATF7IP L 9 NAT1 8260 ARD1A L 12 SERPINA3 351 APP L 12 SERPINA3 354 KLK3 L 12 SERPINA3 1215 CMA1 L 12 SERPINA3 1504 CTRB1 L 12 SERPINA3 1506 CTRL L 12 SERPINA3 1511 CTSG L 12 SERPINA3 1990 ELA1 L 12 SERPINA3 1991 ELA2 L 12 SERPINA3 2064 ERBB2 L 12 SERPINA3 2153 F5 L 12 SERPINA3 3817 KLK2 L 12 SERPINA3 4035 LRP1 L 12 SERPINA3 4485 MST1 L 12 SERPINA3 5422 POLA L 12 SERPINA3 64215 DNAJC1 L 14 AAMP 51497 TH1L S 15 AANAT 7534 YWHAZ L 18 ABAT 7915 ALDH5A1 L 19 ABCA1 335 APOA1 L 19 ABCA1 6645 SNTB2 L 19 ABCA1 8772 FADD L 20 ABCA2 55755 CDK5RAP2 L 22 ABCB7 2235 FECH L 23 ABCF1 3692 ITGB4BP S 24 ABCA4 1258 CNGB1 L 25 ABL1 27 ABL2 L 25 ABL1 472 ATM L 25 ABL1 613 BCR L 25 ABL1 718 C3 L 25 ABL1 867 CBL L 25 ABL1 1501 CTNND2 L 25 ABL1 2048 EPHB2 L 25 ABL1 2547 XRCC6 L 25 ABL1 2876 GPX1 L 25 ABL1 2885 GRB2 L 25 ABL1 3055 HCK L 25 ABL1 3636 INPPL1 L 25 ABL1 3716 JAK1 L 25 ABL1 4193 MDM2 L 25 ABL1 4690 NCK1 L 25 ABL1 4914 NTRK1 L 25 ABL1 5062 PAK2 L 25 ABL1 5295 PIK3R1 L 25 ABL1 5335 PLCG1 L 25 ABL1 5591 -
GGA1 (D-6): Sc-271927
SANTA CRUZ BIOTECHNOLOGY, INC. GGA1 (D-6): sc-271927 BACKGROUND APPLICATIONS The GGA family of proteins (Golgi-localized, g-adaptin ear-containing, ARF- GGA1 (D-6) is recommended for detection of GGA1 of human origin by binding proteins) are ubiquitous coat proteins that facilitate the trafficking Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), of soluble proteins from the trans-Golgi network (TGN) to endosomes/lyso- immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell somes by means of interactions with TGN-sorting receptors, ARF (ADP-ribo- lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- sylation factor) and Clathrin. Members of the GGA family, GGA1, GGA2 (also 1:500), immunohistochemistry (including paraffin-embedded sections) known as VEAR) and GGA3, are multidomain proteins that bind mannose 6- (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA phosphate receptors (MPRs). GGAs have modular structures with an N-termi- (starting dilution 1:30, dilution range 1:30-1:3000). nal VHS (VPS-27, Hrs and STAM) domain followed by a GAT (GGA and TOM1) Suitable for use as control antibody for GGA1 siRNA (h): sc-41167, GGA1 domain, a connecting hinge segment and a C-terminal GAE ( -adaptin ear) g shRNA Plasmid (h): sc-41167-SH and GGA1 shRNA (h) Lentiviral Particles: domain. The amino-terminal VHS domains of GGAs form complexes with sc-41167-V. the cytoplasmic domains of sorting receptors by recognizing acidic-cluster di-leucine (ACLL) sequences. GGA1 and GGA2 do not associate with each Molecular Weight of GGA1: 85 kDa. -
Association Between GGA1 Gene Polymorphisms and Occurrence of Mammary Mixed Tumors and Aging in Domestic Bitches1)
34 Med. Weter. 2016, 72 (1), 34-40 Praca oryginalna Original paper Association between GGA1 gene polymorphisms and occurrence of mammary mixed tumors and aging in domestic bitches1) WIESŁAWA KRANC*, ADRIAN CHACHUŁA**, KATARZYNA WOJTANOWICZ-MARKIEWICZ***, KATARZYNA ZAORSKA**, EDYTA OCIEPA***, ADAM PIOTROWSKI*, DOROTA BUKOWSKA***, SYLWIA CIESIÓŁKA**, SYLWIA BORYS****, HANNA PIOTROWSKA****, AGNIESZKA SKOWROŃSKA*****, MARCIN NOWAK******, PAWEŁ ANTOSIK***, KLAUS-PETER BRÜSSOW***, BARTOSZ KEMPISTY*, **, MAŁGORZATA BRUSKA*, MICHAŁ NOWICKI**, MACIEJ ZABEL**, ******* *Department of Anatomy, **Department of Histology and Embryology, Medicine Faculty I, Poznan University of Medical Sciences, Swiecickiego 6 St., 60-781 Poznan, Poland ***Institute of Veterinary Sciences, Faculty of Animal Breeding and Biology, Poznan University of Life Sciences, Wolynska 35 St., 60-637 Poznan, Poland ****Department of Toxicology, Faculty of Farmacy, Poznan University of Medical Sciences, Dojazd 30 St., 60-631 Poznan, Poland *****Department of Human Physiology, Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland ******Department of Pathology, Faculty of Veterinary Medicine, Wroclaw University of Life Sciences, C. K. Norwida 31 St., 50-375 Wrocław, Poland *******Department of Histology and Embryology, Wroclaw Medical University, 6a Chalubinskiego St., 50-368, Wroclaw, Poland Received 13.07.2015 Accepted 03.11.2015 Kranc W., Chachuła A., Wojtanowicz-Markiewicz K., Zaorska K., Ociepa E., Piotrowski A., Bukowska D., Ciesiółka S., Borys S., Piotrowska H., Skowrońska A., Nowak M., Antosik P., Brüssow K.-P., Kempisty B., Bruska M., Nowicki M., Zabel M. Association between GGA1 gene polymorphisms and occurrence of mammary mixed tumours and aging in domestic bitches Summary In recent years the number of malignant mammary gland tumor occurrences in domestic bitches has increased. -
Sortilin: a Protein Involved in Ldl Metabolism and Atherosclerosis
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2015 Sortilin: A Protein Involved in Ldl Metabolism and Atherosclerosis Kevin Mahendra Patel University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacology Commons, and the Physiology Commons Recommended Citation Patel, Kevin Mahendra, "Sortilin: A Protein Involved in Ldl Metabolism and Atherosclerosis" (2015). Publicly Accessible Penn Dissertations. 1935. https://repository.upenn.edu/edissertations/1935 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1935 For more information, please contact [email protected]. Sortilin: A Protein Involved in Ldl Metabolism and Atherosclerosis Abstract Genome-wide association studies (GWAS) have been used to identify novel genes and loci that contribute to lipid traits and coronary heart disease (CHD) in a causal manner. A locus on chromosome 1p13, which harbors the gene sortilin-1 (SORT1) encoding the protein sortilin is the locus in the human genome with the strongest association with low-density lipoprotein cholesterol (LDL-C) and is also one of the strongest loci associated with CHD. Homozygosity for the minor allele haplotype at 1p13 is associated with a >10 fold increase in hepatic SORT1 expression, a mean 16 mg/dL reduction in plasma LDL-C, and a 40% reduction in CHD risk. Sortilin has been extensively studied in the central nervous system, where it traffics multiple ligands from the Golgi apparatus to the lysosome and also serves as a cell surface endocytosis receptor for a variety of ligands. However, the role of sortilin in other cell types, most notably hepatocytes and macrophages, which are key regulators of lipid metabolism and atherosclerosis development, has not been well studied.